MDS Global Launches an AI-powered Marketing Decision Intelligence Platform “MDS DecisionAI” That Enables Telcos to Reduce Churn and Increase Revenues
Today, MDS Global, a leading provider of converged B2B/B2C billing and BSS solutions, has launched MDS DecisionAI, a new marketing decision intelligence platform that leverages the power of artificial intelligence to provide the critical insight ambitious MNOs, MVNOs, sub-brands and fixed line operators need to grow and outperform the competition.
MDS DecisionAI provides a full suite of telecoms specific AI modules including forecasting, churn, propensity models, and marketing and media mix analysis, that will help brands to optimise their marketing and commercial strategy. It enables them to identify monetisation opportunities and blind spots so they can make interventions sooner.
As a result, operators will be able to maximise yield and revenue, for example by predicting churn and identifying a customer’s propensity to consider other products offered in a cross-sell campaign, or through better-informed proposition development.
As part of MDS Global’s commitment to driving profitable digital telcos, MDS DecisionAI’s SaaS model, makes it a highly flexible and affordable way to operationally deploy AI. This is particularly beneficial for operators, MVNOs and sub brands who haven’t been able to invest in AI in the past due to the complexity of implementation, high integration costs and lack of affordable expert skill. The model eliminates the need for complex, costly and lengthy implementation projects. Instead, it can be easily integrated into existing billing, CVM and digital channels, no matter the platform used. Operators can expect to be set up and reaping the benefits of making more informed strategic decisions within 60 days.
Decision intelligence tools are changing the shape of telecoms with reports of cases where operators have made multi-million-pound revenue improvements from a more reactive churn response, seen 25% increase on cross sell success rates, and 30% uplift in acquisition by reviewing marketing media spend.
John Burton, CEO of MDS Global, says MDS DecisionAI will democratise artificial intelligence and decision intelligence, and make it accessible to all, including small brands: “Only 5%1 of telcos have a full AI marketing and personalisation strategy that is delivering an ROI on expected growth and benefits. MDS DecisionAI is a game changer and makes the vision of becoming a profitable digital telco more achievable.”
“Using MDS DecisionAI will create more agile and successful operators almost overnight. The use of AI will help them make the right commercial and marketing spending decisions and make more informed decisions about when and how to adjust their strategy or invest in innovation.”
More information about how AI is changing the telco landscape and supporting digital telco strategies is available here. Operators can also request a demo here.
About MDS Global
MDS Global is a leading provider of converged B2B/B2C billing and BSS solutions to MNOs, MVNOs, MVNEs and fixed line telcos. We power our customers’ transition from connectivity providers to digital service providers with carrier-grade solutions that include our cloud monetisation platform, AI-powered marketing decision intelligence platform, eSIM, and self-care apps portals.
Our agile “No code” SaaS solutions enable communications service providers to drive profit growth, deliver delightful digital customer experiences and launch innovative services fast.
To find out more, visit www.mdsglobal.com or follow us on LinkedIn and Twitter .
1 Unlocking the value of personalization at scale for operators, McKinsey, February 2022
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005875/en/
Contact information
MDS Global press contact
Corine Suscens
Head of Global Marketing
marketing@mdsglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas12.1.2026 14:30:00 EET | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France’s National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol for botensilimab (BOT) plus balstilimab (BAL) under France’s Autorisation d’Accès Compassionnel (AAC) framework. The updated protocol expands France’s previously granted AAC authorization for BOT+BAL in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases to eligible patients with certain ovarian cancers and soft-tissue sarcomas—diseases with substantial unmet medical need after standard options have been exhausted. The revised protocol is designed to broaden the eligibility criteria, allowing more patients with advanced solid tumors to have early access to BOT+BAL under reimbursed compassionate use, and to enhance monitoring and treatment procedures in participating hospitals. BOT+BAL is a chemotherapy- and radiation-f
Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands12.1.2026 14:30:00 EET | Press release
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity. Cell therapy manufacturing is patient-specific and time-sensitive, making regional production capacity increasingly important as programs advance from clinical development toward commercial supply. The new Netherlands hub is designed to provide European drug developers with access to automated manufacturing infrastructure, while maintaining alignment to a common production standard across Cellares’ global facilities. The leased premises comprise approximately 9,741 square meters (about 105,000 square feet LFA) of laboratory and office space within the Nexus building in Leiden, a newly construct
Lilac and Traxys Announce Binding 10-Year Offtake Agreement for Great Salt Lake Lithium Production12.1.2026 14:00:00 EET | Press release
Lilac Solutions, a leading provider of direct lithium extraction technology, and Traxys North America, a leading global physical trader and merchant in metals and natural resources, today announced a binding 10-year offtake agreement for lithium carbonate produced at Lilac's Great Salt Lake facility in Utah. The agreement represents a major milestone in advancing the project toward construction and establishes a clear commercial pathway for one of the nearest-term domestic lithium projects in the United States. Under the terms of the definitive agreement, Traxys will purchase 50,000 tonnes of lithium carbonate over a 10-year period, representing 100% of the planned Phase 1 production capacity. The agreement is take-or-pay, with agreed pricing mechanisms linked to market indices. The Great Salt Lake Phase 1 facility is designed to produce 5,000 tonnes per annum of battery-grade lithium carbonate, which would nearly double current U.S. lithium carbonate production. The project leverages
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 07:00:00 EET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 03:15:00 EET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom